From Nasdaq:



Alkermes stock closed at $27.92, which was a 1.34% increase from the previous day and outperformed the S&P 500 and Dow. The stock has risen by 13% in the past month, indicating strong performance. Analysts are projecting an increase in earnings per share and revenue for the company. Recent changes to analyst estimates for Alkermes depict positivity toward the company’s business operations. Alkermes has a Zacks Rank of #3 (Hold) and is currently trading at a Forward P/E ratio of 17.66. The Medical – Biomedical and Genetics industry, to which Alkermes belongs, has a Zacks Industry Rank of 68, placing it in the top 27% of all 250+ industries. Zacks is also providing tips on the top 10 stocks for 2024 and offering a free stock analysis report. The article emphasizes the importance of tracking stock-moving metrics through Zacks.com in the upcoming trading sessions.



Original: Alkermes (ALKS) Outperforms Broader Market: What You Need to Know